Home / Health / Detected during antibody testing can prevent people from getting COVID

Detected during antibody testing can prevent people from getting COVID


There is a small molecule that neutralizes the coronavirus, which is seen in tests on mice and hamsters. This discovery may be the key to preventing people from contracting the virus.

Doctors Steven Shapiro and John Mellors of the University of Pittsburgh’s School of Medicine believe in a small antibody association. AB8 can cause the end of the pandemic.

It can be given before a patient is ill to prevent the disease, but if the patient has the disease, it can be used to prevent the virus from entering the cell when it is already there. So it both treats and prevents, says Shapiro, executive vice president of the Pittsburgh School of Medicine.

Mellors, head of the infectious diseases department, said he was thinking of AB8 as a lock and key system. “It prevents the key from entering the lock, blocking that entrance, so the virus cannot infect the cells and cause the cell to die and spread.”


The small size of the AB8 is what makes it so potent yet effective. The association can reach places that other treatments simply cannot. This also means that doctors can administer it in various ways, for example by inhalation or by injecting it under the skin.

Researchers want to assure people that the compound does not bind to human cells, which means that it will not have negative side effects.

“The timeline, to be brief, is the beginning of 2021,” says Mellors. “To manufacture, make safety assessments of other animals, to obtain FDA approval and to record and record clinical trials.”

From now on, it is licensed for global development, so the hope is that AB8 can fight, destroy and even prevent COVID-19.

WINK News Health and Medical Reporter Veronica Marshall contacted other health experts for their views on AB8.

“This is a very interesting development; the small size of the antibody fragment can make it useful in aerosol formulations, says Dr. Dennis Burton with Scripps Research.

Source link